Medication exposure in a pregnancy risk evaluation program [poster] Conference Poster uri icon
  • Our knowledge of safe medication use during pregnancy is limited, due to lack of rigorous studies evaluating birth outcomes associated with in utero exposure to medications. HealthPartners Research Foundation, through its participation in the Center for Education and Research on Therapeutics (CERT) within the HMO Research Network (HMORN), is participating in a new collaborative research program, the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP)s. The collaboration is between the Food and Drug Administration (FDA), additional sites within the HMO Research Network, Kaiser Permanente Northern and Southern California, and Vanderbilt University and has been funded to enable ongoing study of medication use and outcomes in pregnancy. Our program aims to develop common, necessary data linkages across participating sites to allow for multiple studies of birth outcomes associated with in-utero exposure to medications. Specific components of the program include: 1) maternal-infant record linkage of all women delivering an infant between 2001 and 2007, 2) linkage to birth certificate data for infants delivered between 2001 and 2007, 3) validation of data elements within the datasets through medical chart abstractions, and 4) annual update of the datasets. Data files on maternal and child enrollment, outpatient drug dispensing data, and inpatient and outpatient diagnoses and procedures, in addition to data elements obtained from birth certificate data, will be developed and maintained at each of the program sites. This poster describes the data obtained to date, specifically within HPRF.

  • publication date
  • 2010
  • Research
  • Data Systems
  • Drugs and Drug Therapy
  • Pregnancy
  • Risk Factors